Literature DB >> 23519222

Treatment of post-electroconvulsive therapy agitation with dexmedetomidine.

Matthew B Cohen1, Jonathan T Stewart.   

Abstract

Post-electroconvulsive therapy (ECT) delirium is commonly encountered in practice, occurring in up to 12% of treatments. Although often easily managed nonpharmacologically, more severe or persistent cases are generally treated with benzodiazepines or propofol. We describe a patient who failed to respond adequately to these medications but responded quite favorably to dexmedetomidine, a centrally acting α2 agonist. There is evidence that dexmedetomidine may have unique, "delirium-sparing" properties; this makes it an attractive option for this indication.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519222     DOI: 10.1097/YCT.0b013e31827e56a7

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  4 in total

1.  A comparison of dexmedetomidine with propofol versus esmolol with propofol to attenuate the hemodynamic stress responses after electroconvulsive therapy.

Authors:  Radhe Sharan; Neeru Bala; Joginder Pal Attri; Keerty Garg
Journal:  Indian J Psychiatry       Date:  2017 Jul-Sep       Impact factor: 1.759

2.  Dexmedetomidine for the management of postictal agitation after electroconvulsive therapy with S-ketamine anesthesia.

Authors:  Suna Su Aksay; Jan Malte Bumb; Dmitry Remennik; Manfred Thiel; Laura Kranaster; Alexander Sartorius; Christoph Janke
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-23       Impact factor: 2.570

3.  Dexmedetomidine Regulates the miR-146a-5p/NF-κB Axis to Alleviate Electroconvulsive Therapy-Induced Cognitive Impairments.

Authors:  Xiaohui Zhou; Peipei Si; Li Wang; Huiqun Jia
Journal:  Comput Math Methods Med       Date:  2022-10-04       Impact factor: 2.809

4.  Amlodipine and the Successful Management of Post-Electroconvulsive Therapy Agitation.

Authors:  Ali Shahriari; Maryam Khooshideh; Mahdi Sheikh
Journal:  Case Rep Psychiatry       Date:  2016-02-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.